Larotrectinib Response in NTRK3 Fusion-Driven Diffuse High-Grade Glioma

High-grade glioma (HGG) and glioblastoma are the most common adult malignant brain tumors. The standard treatment consists of surgical resection followed by radiochemotherapy with temozolomide. The prognosis and the therapeutic options of these malignant brain tumors however are limited. Here, we de...

Descripción completa

Detalles Bibliográficos
Autores principales: König, David, Hench, Jürgen, Frank, Stephan, Dima, Laura, Bratic Hench, Ivana, Läubli, Heinz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254302/
https://www.ncbi.nlm.nih.gov/pubmed/35526519
http://dx.doi.org/10.1159/000524399
_version_ 1784740667248869376
author König, David
Hench, Jürgen
Frank, Stephan
Dima, Laura
Bratic Hench, Ivana
Läubli, Heinz
author_facet König, David
Hench, Jürgen
Frank, Stephan
Dima, Laura
Bratic Hench, Ivana
Läubli, Heinz
author_sort König, David
collection PubMed
description High-grade glioma (HGG) and glioblastoma are the most common adult malignant brain tumors. The standard treatment consists of surgical resection followed by radiochemotherapy with temozolomide. The prognosis and the therapeutic options of these malignant brain tumors however are limited. Here, we describe a case of a patient with HGG with a previously unknown NTRK3 fusion that showed an extraordinary response to treatment with larotrectinib. This case supports regular testing for NTRK fusion proteins.
format Online
Article
Text
id pubmed-9254302
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-92543022022-09-23 Larotrectinib Response in NTRK3 Fusion-Driven Diffuse High-Grade Glioma König, David Hench, Jürgen Frank, Stephan Dima, Laura Bratic Hench, Ivana Läubli, Heinz Pharmacology Brief Report High-grade glioma (HGG) and glioblastoma are the most common adult malignant brain tumors. The standard treatment consists of surgical resection followed by radiochemotherapy with temozolomide. The prognosis and the therapeutic options of these malignant brain tumors however are limited. Here, we describe a case of a patient with HGG with a previously unknown NTRK3 fusion that showed an extraordinary response to treatment with larotrectinib. This case supports regular testing for NTRK fusion proteins. S. Karger AG 2022-05-06 /pmc/articles/PMC9254302/ /pubmed/35526519 http://dx.doi.org/10.1159/000524399 Text en Copyright © 2022 by The Author(s). Published by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
spellingShingle Brief Report
König, David
Hench, Jürgen
Frank, Stephan
Dima, Laura
Bratic Hench, Ivana
Läubli, Heinz
Larotrectinib Response in NTRK3 Fusion-Driven Diffuse High-Grade Glioma
title Larotrectinib Response in NTRK3 Fusion-Driven Diffuse High-Grade Glioma
title_full Larotrectinib Response in NTRK3 Fusion-Driven Diffuse High-Grade Glioma
title_fullStr Larotrectinib Response in NTRK3 Fusion-Driven Diffuse High-Grade Glioma
title_full_unstemmed Larotrectinib Response in NTRK3 Fusion-Driven Diffuse High-Grade Glioma
title_short Larotrectinib Response in NTRK3 Fusion-Driven Diffuse High-Grade Glioma
title_sort larotrectinib response in ntrk3 fusion-driven diffuse high-grade glioma
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254302/
https://www.ncbi.nlm.nih.gov/pubmed/35526519
http://dx.doi.org/10.1159/000524399
work_keys_str_mv AT konigdavid larotrectinibresponseinntrk3fusiondrivendiffusehighgradeglioma
AT henchjurgen larotrectinibresponseinntrk3fusiondrivendiffusehighgradeglioma
AT frankstephan larotrectinibresponseinntrk3fusiondrivendiffusehighgradeglioma
AT dimalaura larotrectinibresponseinntrk3fusiondrivendiffusehighgradeglioma
AT bratichenchivana larotrectinibresponseinntrk3fusiondrivendiffusehighgradeglioma
AT laubliheinz larotrectinibresponseinntrk3fusiondrivendiffusehighgradeglioma

Ejemplares similares